top of page

LatstNews

News Center

Check out the latest news from Ocelot Bio.

Latest News

November 4, 2022

Ocelot Bio Presents Phase 1 Data Highlighting Activity and Safety of OCE-205 at AASLD The Liver Meeting

®

October 24, 2022

Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity and Safety of OCE-205 at AASLD The Liver Meeting

®

August 22, 2022

Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Hepatorenal Syndrome

March 23, 2022

Ocelot Bio Closes $36 Million Series A Financing, Appoints Katherine Vega Stultz as President and Chief Executive Officer

Patients can’t wait and neither will we.

Our passion for improving the lives of people with severe complications of liver disease is the foundation of our company.

bottom of page